Background: SARS-CoV-2 Virus can trigger severe pneumonia and lead to acute respiratory distress syndrome. Data from clinical, in vitro, and in vivo suggest that virus-induced cytokine dysregulation is a contributory factor to the pathogenesis. Drugs targeting the same are being tried. Methods: To obtain a better understanding of the molecular events, we studied the transcriptome of infected macrophages and obtained a list of incriminated pathways using Gene Set Enrichment Analysis. Co-expression gene analysis was further used to predict drug targets. Results: COVID-19 is characterized by a dysregulation of not only immune pathways, but of hemostasis, intercellular signaling, endothelium, cellular protein metabolism, trans-cellular transport and neuronal activity. Interferon alpha, beta, and gamma are upregulated. IL-1,4, 6,10, 12 13, TNF, NF-KB are upregulated. Signaling by NOTCH, and MAP kinase-6, 4 signaling are increased. Olfactory sensation, transmission across chemical synapses, and sperm motility appear to be downregulated. Disease host signature has some resemblance with cystic fibrosis, SARS infection, and diseases of programmed cell death like neurodegenerative diseases. 24 drugs are predicted including Sulindac, Pancuronium, Etamsylate, Ciclosporin, Ciprofloxacin, Valproic Acid, Triamcinolone, Tanespimycin, Tretinoin, Monorden, Scopolamine, Captopril, and Thalidomide. Conclusions: The effectiveness of this approach is demonstrated by the current level of evidence in understanding of COVID-19 pathophysiology. Several drugs of the same drug class have been used in COVID-19 treatment as predicted through the analysis. Further biomarker studies, drug testing on COVID infected cell-lines, and clinical studies are required for validation of obtained results.